Company news

Imunon, Inc. news in 2023

Imunon, Inc.'s news releases, calls and decks from 2023, newest first.

View company

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 10, 2023

IMUNON’s VP of R&D to Present at the Vaccines Summit-2023

November 13, 2023

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

November 13, 2023

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

November 6, 2023

IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress

October 22, 2023

IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations

October 18, 2023

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

October 17, 2023

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

October 5, 2023

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

September 27, 2023

IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies

September 25, 2023

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4: 00 p.m. ET

September 12, 2023

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4: 00 p.m. ET

September 6, 2023

IMUNON to Participate in the H.C. Wainwright Global Investment Conference

September 4, 2023

IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus

August 23, 2023

IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla

August 13, 2023

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023

Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

August 6, 2023

IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus

June 26, 2023

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

June 25, 2023

IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference

May 29, 2023

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

May 3, 2023

IMUNON Reports 2022 Financial Results and Provides Business Update

March 29, 2023

IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting

March 14, 2023

IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer

February 26, 2023

IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses

January 11, 2023

IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform

January 4, 2023

Calls in 2023

Decks in 2023